Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Nathan C. Nussbaum"'
Autor:
Alexander Liede, Rohini K. Hernandez, Sally W. Wade, Ronghai Bo, Nathan C. Nussbaum, Elizabeth Ahern, William C. Dougall, Mark J. Smyth
Publikováno v:
OncoImmunology, Vol 7, Iss 12 (2018)
After a case report of profound clinical response in a melanoma patient following treatment with an immune checkpoint inhibitor (ICI) and RANK-ligand inhibitor denosumab, we identified similar patients from electronic health records (EHR) and describ
Externí odkaz:
https://doaj.org/article/b10ac2dd6b934fe491245e01e9a27a05
Publikováno v:
Health Services Research
Objective We expanded the previous assessment of a mortality variable suited for real‐world evidence‐focused oncology research. Data source We used a nationwide electronic health record (EHR)‐derived de‐identified database. Data collection We
Autor:
Aracelis Z, Torres, Nathan C, Nussbaum, Christina M, Parrinello, Ariel B, Bourla, Bryan E, Bowser, Samuel, Wagner, David C, Tabano, Daniel, George, Rebecca A, Miksad
Publikováno v:
Advances in therapy. 39(6)
We previously demonstrated that real-world progression (rwP) can be ascertained from unstructured electronic health record (EHR)-derived documents using a novel abstraction approach for patients with advanced non-small cell lung cancer (base case). T
Autor:
Brandon Arnieri, Deborah Kuk, Rachael Sorg, Neal J. Meropol, Michael Taylor, Gillis Carrigan, Melisa Tucker, Patricia Luhn, Rebecca Rohrer, Nathan C. Nussbaum
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Medical Research Methodology
BMC Medical Research Methodology
Background The use of real-world data to generate evidence requires careful assessment and validation of critical variables before drawing clinical conclusions. Prospective clinical trial data suggest that anatomic origin of colon cancer impacts prog
Autor:
Rachael Sorg, Anne C. Chiang, Janina A. Longtine, Roy S. Herbst, Kerin B. Adelson, Pamela R. Soulos, Carolyn J Presley, Cary P. Gross, Fauzia Riaz, Amy P. Abernethy, Vineeta Agarwala, Nathan C. Nussbaum
Publikováno v:
Journal of Geriatric Oncology. 10:669-672
Autor:
Joshua S. Kraut, Ariel Bulua Bourla, Xinran Ma, Nathan C. Nussbaum, Kelly Magee, Bryan Bowser, Lawrence Bellomo, Meghna Samant, Olga Tymejczyk, Caroline S. Bennette, Melisa Tucker
Publikováno v:
Advances in Therapy
Introduction Effectiveness metrics for real-word research, analogous to clinical trial ones, are needed. This study aimed to develop a real-world response (rwR) variable applicable to solid tumors and to evaluate its clinical relevance and meaningful
Publikováno v:
Cancer Research. 80:5772-5772
Objective: In oncology research, mortality, as a variable, and overall survival (OS), as an efficacy endpoint, are critical. As real-world data gains use in supporting regulatory decisions, assessing the validity of mortality data is important. Morta
Autor:
Mark J. Smyth, Rohini K. Hernandez, Elizabeth Ahern, Alexander Liede, Sally W. Wade, Ronghai Bo, Nathan C. Nussbaum, William C. Dougall
Publikováno v:
OncoImmunology, Vol 7, Iss 12 (2018)
After a case report of profound clinical response in a melanoma patient following treatment with an immune checkpoint inhibitor (ICI) and RANK-ligand inhibitor denosumab, we identified similar patients from electronic health records (EHR) and describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119b0ed260a20d7847909733609b71a4
https://europepmc.org/articles/PMC6279336/
https://europepmc.org/articles/PMC6279336/
Autor:
Anne C. Chiang, Jeremy M. O’Connor, Kathi Seidl-Rathkopf, Jean Steiner, Kenneth R. Carson, Amy P. Abernethy, Cary P. Gross, Kristen L Fessele, Carolyn J Presley, Nathan C. Nussbaum, Joseph S. Ross, Emily S. Yin, Kerin B. Adelson
IMPORTANCE: The US Food and Drug Administration (FDA) is increasing its pace of approvals for novel cancer therapeutics, including for immune checkpoint inhibitors of programmed cell death 1 protein (anti–PD-1 agents). However, little is known abou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b4d6edb57edbb5b0827cc91818929c7
https://europepmc.org/articles/PMC6143052/
https://europepmc.org/articles/PMC6143052/
Autor:
Shannon E. Lee, David E. Light, Anala Gossai, Sean Khozin, Aracelis Z. Torres, Amy P. Abernethy, Rachael Sorg, Jizu Zhi, Payal Patel, Gideon M. Blumenthal, Melissa D. Curtis, Nathan C. Nussbaum, Richard Pazdur, Melisa Tucker
Publikováno v:
The oncologist. 23(3)
Background Evidence from cancer clinical trials can be difficult to generalize to real-world patient populations, but can be complemented by real-world evidence to optimize personalization of care. Further, real-world usage patterns of programmed cel